209 related articles for article (PubMed ID: 25039779)
21. Nanoparticle transport across the blood brain barrier.
Grabrucker AM; Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
Tissue Barriers; 2016; 4(1):e1153568. PubMed ID: 27141426
[TBL] [Abstract][Full Text] [Related]
22. Nano carriers for drug transport across the blood-brain barrier.
Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
[TBL] [Abstract][Full Text] [Related]
23. Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway.
Kuo YC; Shih-Huang CY
J Drug Target; 2013 Sep; 21(8):730-8. PubMed ID: 23815407
[TBL] [Abstract][Full Text] [Related]
24. Targeting central nervous system pathologies with nanomedicines.
Mizrahy S; Gutkin A; Decuzzi P; Peer D
J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
[TBL] [Abstract][Full Text] [Related]
25. ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier.
Dal Magro R; Ornaghi F; Cambianica I; Beretta S; Re F; Musicanti C; Rigolio R; Donzelli E; Canta A; Ballarini E; Cavaletti G; Gasco P; Sancini G
J Control Release; 2017 Mar; 249():103-110. PubMed ID: 28153761
[TBL] [Abstract][Full Text] [Related]
26. Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles.
Kucharz K; Kristensen K; Johnsen KB; Lund MA; Lønstrup M; Moos T; Andresen TL; Lauritzen MJ
Nat Commun; 2021 Jul; 12(1):4121. PubMed ID: 34226541
[TBL] [Abstract][Full Text] [Related]
27. Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.
Hsu J; Rappaport J; Muro S
Pharm Res; 2014 Jul; 31(7):1855-66. PubMed ID: 24558007
[TBL] [Abstract][Full Text] [Related]
28. Receptor-mediated transport of therapeutics across the blood-brain barrier.
Friden PM
Neurosurgery; 1994 Aug; 35(2):294-8; discussion 298. PubMed ID: 7969837
[TBL] [Abstract][Full Text] [Related]
29. Brain iron homeostasis.
Moos T
Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
[TBL] [Abstract][Full Text] [Related]
30. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
Fornaguera C; Dols-Perez A; Calderó G; García-Celma MJ; Camarasa J; Solans C
J Control Release; 2015 Aug; 211():134-43. PubMed ID: 26057857
[TBL] [Abstract][Full Text] [Related]
31. Macromolecular drug transport into the brain using targeted therapy.
Lichota J; Skjørringe T; Thomsen LB; Moos T
J Neurochem; 2010 Apr; 113(1):1-13. PubMed ID: 20015155
[TBL] [Abstract][Full Text] [Related]
32. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
[TBL] [Abstract][Full Text] [Related]
33. Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain.
Anraku Y; Kuwahara H; Fukusato Y; Mizoguchi A; Ishii T; Nitta K; Matsumoto Y; Toh K; Miyata K; Uchida S; Nishina K; Osada K; Itaka K; Nishiyama N; Mizusawa H; Yamasoba T; Yokota T; Kataoka K
Nat Commun; 2017 Oct; 8(1):1001. PubMed ID: 29042554
[TBL] [Abstract][Full Text] [Related]
34. Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration.
Karaoglu Hanzatian D; Schwartz A; Gizatullin F; Erickson J; Deng K; Villanueva R; Stedman C; Harris C; Ghayur T; Goodearl A
MAbs; 2018 Jul; 10(5):765-777. PubMed ID: 29771629
[TBL] [Abstract][Full Text] [Related]
35. Lactoferrin coated or conjugated nanomaterials as an active targeting approach in nanomedicine.
Agwa MM; Sabra S
Int J Biol Macromol; 2021 Jan; 167():1527-1543. PubMed ID: 33212102
[TBL] [Abstract][Full Text] [Related]
36. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
Pardridge WM
Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
[TBL] [Abstract][Full Text] [Related]
37. Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex.
Kang T; Jiang M; Jiang D; Feng X; Yao J; Song Q; Chen H; Gao X; Chen J
Mol Pharm; 2015 Aug; 12(8):2947-61. PubMed ID: 26149889
[TBL] [Abstract][Full Text] [Related]
38. Evolution of Nanoparticle Protein Corona across the Blood-Brain Barrier.
Cox A; Andreozzi P; Dal Magro R; Fiordaliso F; Corbelli A; Talamini L; Chinello C; Raimondo F; Magni F; Tringali M; Krol S; Jacob Silva P; Stellacci F; Masserini M; Re F
ACS Nano; 2018 Jul; 12(7):7292-7300. PubMed ID: 29953205
[TBL] [Abstract][Full Text] [Related]
39. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
Ulbrich K; Hekmatara T; Herbert E; Kreuter J
Eur J Pharm Biopharm; 2009 Feb; 71(2):251-6. PubMed ID: 18805484
[TBL] [Abstract][Full Text] [Related]
40. Upconversion Nanoparticle-Based Strategy for Crossing the Blood-Brain Barrier to Treat the Central Nervous System Disease.
Fu L; Chung R; Shi B
Methods Mol Biol; 2019; 2054():263-282. PubMed ID: 31482461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
